Lexaria Bioscience Corporation Updates on GLP-1 Study Outcomes
Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently shared significant developments regarding its Phase 1b, 12-week chronic study identified as GLP-1-H24-4. This study centered on their innovative DehydraTECH (DHT) formulations compared against the well-known Rybelsus (semaglutide), the leading oral GLP-1 medication offered by Novo Nordisk A/S (NYSE: NVO).
Positive Results Highlight Safety and Efficacy
In a statement by Richard Christopher, CEO of Lexaria, he expressed immense satisfaction with the study results. The primary endpoint of the research was successfully achieved, showcasing a significant reduction in unwanted side effects, nearly halved when comparing the DHT formulations to Rybelsus.
Study Structure and Findings
The study comprised a total treatment duration of 12 weeks, succeeded by a follow-up phase lasting 4 weeks. The outcomes demonstrated that all four DHT formulations both proved safe and were well-tolerated by participants. Crucially, the data indicated lower instances of treatment-emergent adverse events (AE) and gastrointestinal AEs in the DHT arms when juxtaposed with the Rybelsus control arm.
DHT-Semaglutide Shows Superior Results
Among the DHT formulations tested, the DHT-semaglutide formulation emerged as the leader, showcasing a remarkable 47.9% reduction in total adverse events compared to the Rybelsus medication. Moreover, there was an impressive 54.9% decrease observed in gastrointestinal AEs associated with DHT-semaglutide versus Rybelsus.
Examining Efficacy Across Key Metrics
While evaluating the primary efficacy measure of HbA1c reduction, it was noted that both DHT-semaglutide and Rybelsus exhibited comparable results. However, it is essential to highlight that the Rybelsus control arm showed superior efficacy in body weight reduction at both the week 12 and week 16 evaluations, a finding that was consistent with the earlier 8-week interim analysis.
Planning Future Research and Development
Lexaria is excited about the results from their recent DHT-semaglutide formulation, and they see a promising path for further development. Upcoming research will likely include salcaprozate sodium (SNAC), utilized in earlier studies (GLP-1-H24-1 and GLP-1-H24-2) but absent in the current analysis.
Next Steps and Continued Commitment
The pharmaceutical company aims to explore options for conducting follow-up clinical trials, refining the DehydraTECH formulation combined with SNAC, and testing this against the Rybelsus treatment. Such studies will build on previous findings from their compendium of studies GLP-1-H24-1, GLP-1-H24-2, and GLP-1-H24-4, ensuring Lexaria remains at the forefront of innovative treatment options.
Sharing Results with Partners
In addition to their own research development, Lexaria plans to share the complete dataset from GLP-1-H24-4 with a partnering pharmaceutical entity as per a Material Transfer Agreement (MTA). This agreement has been extended until April 30, 2026, to provide adequate time for thorough data evaluation, and further announcements are anticipated.
Market Performance Update
Following these announcements, LEXX stock has experienced a decline of 7.42%, currently trading at approximately $0.63. This is a crucial time for investors and stakeholders as Lexaria continues to pursue innovative solutions in the pharmaceutical landscape.
Frequently Asked Questions
What is the primary purpose of the GLP-1-H24-4 study?
The study aims to evaluate the safety and efficacy of Lexaria's DehydraTECH formulations compared to Novo Nordisk's Rybelsus.
How did Lexaria's formulations perform in terms of side effects?
Lexaria's DHT-semaglutide showed a 47.9% reduction in total adverse events compared to Rybelsus.
What is next for Lexaria after the study?
Lexaria plans to explore further clinical trials involving their formulations combined with SNAC against Rybelsus.
Will results from the study be shared with anyone?
Yes, Lexaria will provide the full dataset to a pharmaceutical partner under an ongoing Material Transfer Agreement (MTA).
How is LEXX stock performing after these updates?
As of the latest check, LEXX stock is down 7.42% at $0.63.
